The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia

被引：0
|
作者：
Arai, D. [1 ]
Kido, R. [1 ]
Yamaguchi, J. [1 ]
Kamimoto, S. [1 ]
Furuya, S. [1 ]
Kanzawa, A. [1 ]
Miyazaki, M. [1 ]
Baba, R. [1 ]
Okamori, S. [1 ]
Takahashi, H. [1 ]
Nakachi, I. [1 ]
机构：
[1] Saiseikai Utsunomiya Hosp, Dept Internal Med, Pulm Div, Utsunomiya, Tochigi, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.537
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
451P
引用
收藏
页码：S1638 / S1639
页数：2
相关论文
共 50 条
  • [21] Plain language summary of a clinical study: anamorelin for treatment of Japanese people with non-small cell lung cancer and cachexia
    Takayama, Koichi
    FUTURE ONCOLOGY, 2024,
  • [22] Safety and efficacy of anlotinib hydrochloride capsules in advanced non-small-cell lung cancer: a multicenter, real-world study
    Wang, Meng
    Mao, Mengxia
    Yang, Yonghua
    Cai, Zhiqiang
    Li, Yan
    Chen, Yuanyuan
    Cai, Jun
    Ye, Qingqing
    FUTURE ONCOLOGY, 2023, 19 (25) : 1729 - 1739
  • [23] Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial
    Koichi Takayama
    Nobuyuki Katakami
    Takuma Yokoyama
    Shinji Atagi
    Kozo Yoshimori
    Hiroshi Kagamu
    Hiroshi Saito
    Yuichi Takiguchi
    Keisuke Aoe
    Akira Koyama
    Naoyuki Komura
    Kenji Eguchi
    Supportive Care in Cancer, 2016, 24 : 3495 - 3505
  • [24] Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial
    Takayama, Koichi
    Katakami, Nobuyuki
    Yokoyama, Takuma
    Atagi, Shinji
    Yoshimori, Kozo
    Kagamu, Hiroshi
    Saito, Hiroshi
    Takiguchi, Yuichi
    Aoe, Keisuke
    Koyama, Akira
    Komura, Naoyuki
    Eguchi, Kenji
    SUPPORTIVE CARE IN CANCER, 2016, 24 (08) : 3495 - 3505
  • [25] A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
    Huanlan Sa
    Yan Shi
    Chunxia Ding
    Kewei Ma
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 7729 - 7742
  • [26] Real-World Case Series on Efficacy and Safety of Amivantamab for EGFR-mutant Non-small Cell Lung Cancer
    Le, X.
    Du, R.
    Lewis, W. E.
    Hong, L.
    Skoulidis, F.
    Byers, L.
    Tsao, A.
    Cascone, T.
    Pozadzides, J.
    Tu, J.
    Negrao, M. V.
    Baik, C.
    Zhang, J.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S484 - S484
  • [27] A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
    Sa, Huanlan
    Shi, Yan
    Ding, Chunxia
    Ma, Kewei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (10) : 7729 - 7742
  • [28] Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study
    Xu, Xiangwei
    Li, Ruya
    Zhu, Peizhen
    Zhang, Penghai
    Chen, Jun
    Lin, Yongsheng
    Chen, Yinqiao
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [29] Efficacy and Safety of Anlotinib-Containing Regimens in Advanced Non-Small Cell Lung Cancer: A Real-World Study
    Sun, Lei
    Zhao, Qi
    Wang, Yanning
    Wang, Yongsheng
    Zheng, Ming
    Ding, Xuansheng
    Miao, Liyun
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2023, 16 : 4165 - 4179
  • [30] Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study
    Xiangwei Xu
    Ruya Li
    Peizhen Zhu
    Penghai Zhang
    Jun Chen
    Yongsheng Lin
    Yinqiao Chen
    World Journal of Surgical Oncology, 19
12345